Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): An open-label, multicentre, randomised phase 3 study

The Lancet Oncology

Volumn 14, Issue 6, 2013, Pages 543-551

  Buikhuisen, Wieneke A ^a   Burgers, Jacobus A ^a   Vincent, Andrew D ^a   Korse, Catharina M ^a   van Klaveren, Rob J ^b   Schramel, Franz M N H ^c   Pavlakis, Nick ^d   Nowak, Anna K ^e   Custers, Frank L J ^f   Schouwink, J Hugo ^g   Gans, Steven J M ^h   Groen, Harry J M ⁱ   Strankinga, Wim F M ^j   Baas, Paul ^a,k  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Lievensberg Hospital   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^f Zuyderland Medical Centre   (Netherlands)

^g MEDISCH SPECTRUM TWENTE   (Netherlands)

^h Sint Jansdal Hospital   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^j BovenIJ Ziekenhuis   (Netherlands)

^k ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; OXYGEN; PEMETREXED; THALIDOMIDE;

ACTIVE SUPPORTIVE CARE; ADULT; AGED; ANEMIA; ARTICLE; BEDTIME DOSAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CONSTIPATION; CONTROLLED STUDY; DISEASE COURSE; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; FUNDING; HEART DISEASE; HISTOPATHOLOGY; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; LEUKOPENIA; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PALLIATIVE THERAPY; PERITONEUM MESOTHELIOMA; PHASE 3 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHI-SQUARE DISTRIBUTION; CISPLATIN; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PALLIATIVE CARE; PLEURAL NEOPLASMS; PROPORTIONAL HAZARDS MODELS; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84876965292     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70125-6     Document Type: Article

References (30)

1. Bianchi C, Bianchi T Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 2007, 45:379-387.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
3. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23:6881-6889.
4. Folkman J Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
5. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 1999, 189:72-78.
6. Van TT, Hanibuchi M, Goto H, et al. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model. Respirology 2012, 17:984-990.
7. Linder C, Linder S, Munck-Wikland E, Strander H Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 1998, 18:2063-2068.
8. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999, 81:54-61.
9. Kumar-Singh S, Vermeulen PB, Weyler J, et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 1997, 182:211-216.
10. Baidas SM, Winer EP, Fleming GF, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000, 18:2710-2717.
11. Lee SM, Rudd R, Woll PJ, et al. Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:5248-5254.
12. Lee SM, Woll PJ, Rudd R, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009, 101:1049-1057.
13. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565-1571.
14. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000, 18:708-715.
15. Baas P, Boogerd W, Dalesio O, Haringhuizen A, Custers F, van Zandwijk N Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005, 48:291-296.
16. van der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BA, Moons KG Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer 2011, 104:1325-1333.
17. Nakano T, Chahinian AP, Shinjo M, et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 1998, 77:907-912.
18. van den Heuvel MM, Korse CM, Bonfrer JM, Baas P Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer 2008, 59:350-354.
19. Yakoub-Agha I, Mary JY, Hulin C, et al. Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myelome. Eur J Haematol 2012, 88:249-259.
20. Dowlati A, Subbiah S, Cooney M, et al. Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. Lung Cancer 2007, 56:377-381.
21. Bartlett JB, Dredge K, Dalgleish AG The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004, 4:314-322.
22. Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012, 30:2509-2515.
23. Dubey S, Janne PA, Krug L, et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol 2010, 5:1655-1661.
24. Laurie SA, Gupta A, Chu Q, et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group. J Thorac Oncol 2011, 6:1950-1954.
25. Jahan T Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer 2012, 76:393-396.
26. Campbell NP, Kunnavakkam R, Leighl N, et al. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer 2012, 78:76-80.
27. Garland LL, Chansky K, Wozniak AJ, et al. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol 2011, 6:1938-1945.
28. Nowak AK, Millward MJ, Creaney J, et al. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol 2012, 7:1449-1456.
29. Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992, 52:3317-3322.
30. Creaney J, Robinson BW Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med 2009, 15:366-370.